相关临床试验
77
14 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1908
进行中（未招募）
2
2.6%
已完成
34
44.2%
尚未招募
12
15.6%
招募中
22
28.6%
暂停
1
1.3%
终止
3
3.9%
撤回
3
3.9%
暂无批准数据
- Entropy Neurodynamics reported 12-week follow-up data from Cohort 1 of its Phase 2 trial of IV-infused psilocin TRP-8803 in treatment-resistant binge eating disorder. - Half of patients had no binge eating episodes across the full 84-day follow-up, with weekly episodes remaining 73% below baseline at 12 weeks. - Anxiety fell 50%, depression 42%, quality of life improved 61% and clinician-rated global impression scores improved 44% at 12 weeks. - The company is now running Cohort 2 with a shorter infusion regimen, with results expected before year end.
- Researchers at Swinburne University of Technology found that sulforaphane, a natural compound in broccoli, can raise levels of frataxin, the protein deficient in Friedreich ataxia. - The compound also protected vulnerable nerve cells from damage and affected cellular stress and inflammation in preclinical models. - Friedreich ataxia is a rare, incurable genetic disease affecting roughly 200 Australians, with no approved treatments specifically for children. - The team is seeking funding for clinical trials, noting sulforaphane's established safety record in adults and children could accelerate its path to patients.
- The Aikenhead Centre for Medical Discovery (ACMD), Australia's first hospital-based biomedical engineering research centre, has opened at St Vincent's Hospital in Fitzroy, Melbourne. - The AU$206 million facility brings together clinicians, scientists, and engineers to fast-track medical discoveries into patient benefits using AI, biotechnology, and regenerative medicine. - The centre can accommodate up to 900 researchers, train 300 new doctors annually, and features 3D printing labs, a kinetics lab, engineering workshops, and robotics. - Research will target chronic conditions including epilepsy, cancer, and osteoarthritis, with the goal of translating laboratory discoveries to the bedside faster and more reliably.
- Tryptamine Therapeutics and Swinburne University have signed an agreement to conduct the world's first clinical trial using intravenous psilocin (TRP-8803) to treat Binge Eating Disorder, with recruitment beginning this quarter. - The open-label trial will enroll 12 participants across two dosage cohorts, building on promising Phase 2a results that showed an earlier oral formulation reduced binge eating episodes by more than 80%. - Binge Eating Disorder, the most common eating disorder in the United States, currently has no specifically approved therapies, highlighting the significant unmet medical need this novel psychedelic-assisted treatment aims to address.
